More News Malaysia

The growth of the pulmonary arterial hypertension market is mainly driven by rising disease awareness, advances in targeted therapies, and an increasing prevalence of risk factors such as connective tissue disorders and congenital heart disease. Additionally, the launch of emerging therapies such as Ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), Seralutinib (GB002) (Gossamer Bio), YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies), and others will further boost the market growth.

LAS VEGAS, May 25, 2026 /PRNewswire/ -- Recently published Pulmonary Arterial Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, pulmonary arterial hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Pulmonary Arterial Hypertension Market Summary

Discover pulmonary arterial hypertension CAGR forecast @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market

Key Factors Driving the Growth of the Pulmonary Arterial Hypertension Market

Ramandeep Singh, Senior Consultant of Forecasting and Analytics at DelveInsight, said that the PAH pipeline remains strong, with next-gen agents like ralinepag showing superior anti-proliferative and vasodilatory activity, Merck's inhaled MK-5475, and innovative treprostinil formulations such as TPIP. These developments are poised to significantly reshape the pulmonary arterial hypertension treatment market landscape in the coming years.

Pulmonary Arterial Hypertension Market Analysis

Pulmonary Arterial Hypertension Competitive Landscape

Some of the PAH drugs under development include Ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), Seralutinib (GB002) (Gossamer Bio), YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies), L606 (liposomal treprostinil) (Pharmosa Biopharm/Liquidia), Treprostinil Palmitil (Insmed Incorporated), CS1 (Cereno Scientific), ROC-101 (AllRock Bio), IKT-001 (Inhibikase Therapeutics), and others.

United Therapeutics' Ralinepag is an innovative, orally administered, highly selective, and potent prostacyclin receptor agonist for the treatment of PAH. Laboratory data show that it binds strongly and selectively to the human prostacyclin (IP) receptor. In Phase II trials, ralinepag suggested the feasibility of once-daily dosing and may offer greater receptor affinity than selexipag.

United Therapeutics is now evaluating ralinepag in the Phase III ADVANCE OUTCOMES registrational trial, a global, multicenter, placebo-controlled study involving patients already receiving approved oral background therapies for PAH. Topline results are anticipated in the first half of 2026.

Respira's lead drug-device candidate, RT234-PAH, is a first-of-its-kind inhaled therapy designed for as-needed use to boost exercise capacity and offer rapid relief from breathlessness and fatigue, the symptoms most commonly reported by patients with PAH (Group 1 under the World Health Organization classification of pulmonary hypertension).

Respira has also been granted Orphan Drug designation by the U.S. Food and Drug Administration for RT234's active ingredient, vardenafil, a potent vasodilator already FDA-approved in oral form for a different indication, and the candidate is currently undergoing Phase II clinical evaluation for PAH.

Liquidia Technologies' YUTREPIA (treprostinil) is an experimental inhaled dry-powder version of treprostinil delivered via a compact, handheld device. The product uses Liquidia's PRINT technology, which creates drug particles with highly uniform size, shape, and composition to improve deposition deep in the lungs when inhaled. Previously known as LIQ861 during early studies, YUTREPIA does not introduce a new mechanism of action, but its development is notable because it offers a more convenient and less burdensome dosing method compared with existing PAH therapies.

The anticipated launch of these emerging therapies are poised to transform the pulmonary arterial hypertension market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the pulmonary arterial hypertension market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about new PAH drugs pipeline @ Pulmonary Arterial Hypertension Drugs

Recent Developments in the Pulmonary Arterial Hypertension Market

What is Pulmonary Arterial Hypertension?

Pulmonary arterial hypertension (PAH) is a rare, progressive condition in which the blood pressure in the arteries that carry blood from the heart to the lungs becomes abnormally high. This happens because the walls of these pulmonary arteries become thickened, narrowed, or stiff, making it harder for blood to flow through. As a result, the heart, especially the right side, must work much harder to pump blood, which can lead to symptoms like shortness of breath, fatigue, chest discomfort, and dizziness. Over time, if untreated, PAH can strain the heart and lead to serious complications, making early recognition and management important.

Pulmonary Arterial Hypertension Epidemiology Segmentation

The pulmonary arterial hypertension epidemiology section provides insights into the historical and current pulmonary arterial hypertension patient pool and forecasted trends for the leading markets. On the basis of class, PAH was bifurcated into Class I, Class II, Class III, and Class IV. In EU4 and the UK, Class III accounted for the maximum number of cases, which was approximately 14,500.

The pulmonary arterial hypertension treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Scope of the Pulmonary Arterial Hypertension Market Report

Download the report to understand PAH market drug class growth trends @ Pulmonary Arterial Hypertension Market Analysis

Table of Contents

Related Reports

Pulmonary Arterial Hypertension Clinical Trial Analysis

Pulmonary Arterial Hypertension Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PAH companies, including Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.

Pulmonary Hypertension Market

Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key pulmonary hypertension companies, including Tenax Therapeutics, Inc., Tectonic Therapeutic, OrphAI Therapeutics, Pharmosa Biopharm Inc., United Therapeutics, Pfizer, Attgeno AB, Cumberland Pharmaceuticals, Pulmovant, Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Foresee Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, ABLi Therapeutics, Inc., 35Pharma Inc., Beijing Continent Pharmaceutical Co, Ltd., Keros Therapeutics, Inc., Bayer, AstraZeneca, Apollo Therapeutics Ltd, and others.

Chronic Pulmonary Hypertension Market

Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic pulmonary hypertension companies, including Bayer, Attgeno AB, Cereno Scientific AB, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie, Tenax Therapeutics, Insmed, Altavant Sciences, and others.

Chronic Thromboembolic Pulmonary Hypertension Market

Chronic Thromboembolic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTEPH companies, including SciPharm Sarl, BAYER, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

...